Physician profile
Chelsee Greer
NPI 1770946824
$437.23
in general payments reported to CMS, 2019-2025
11 companies · $37.50 in 2025
The $37.50 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7.96 · 2023: $59.69 · 2024: $332 · 2025: $37.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $119.69 | 2021-2025 | Unituxin, Unituxin |
| Y-Mabs Therapeutics, INC. | $85.30 | 2024 | Danyelza |
| Alexion Pharmaceuticals, INC. | $53.96 | 2023-2024 | Koselugo |
| Servier Pharmaceuticals LLC | $49.97 | 2023-2024 | |
| Tempus Ai, INC | $28.62 | 2024 | |
| Uswm, LLC | $24.99 | 2024 | Iwilfin |
| Sobi, INC | $22.62 | 2024 | |
| Seagen INC. | $17.64 | 2023 | Adcetris |
| Pfizer INC. | $17.61 | 2024 | |
| Adaptive Biotechnologies Corporation | $16.83 | 2024 | Clonoseq |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsee Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.